文献速递神经核医学肿瘤 PET/CT

记忆门诊环境下早期相18F-氟贝他吡与18F-氟美他莫PET图像作为脑代谢替代指标的研究

Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting.
PubMed 文献 · J Nucl Med · 2022-07-21

在日内瓦记忆中心纳入166例从认知正常到轻度认知障碍及痴呆的受试者,分别接受早期相18F-氟贝他吡(n=94)或18F-氟美他莫(n=72)淀粉样PET及18F-FDG-PET。早期相淀粉样PET与FDG-PET的SUVR呈正相关(R>0.72,p<0.001),两者在AD相关metaROI区分AD患者与对照的AUC分别为0.888和0.801,FDG-PET略优但差异无统计学显著(所有p值高于0.05)。作者认为早期相淀粉样PET成像可替代18F-FDG-PET。

要点

  • 早期相18F-氟贝他吡/18F-氟美他莫与18F-FDG-PET的SUVR呈正相关(R>0.72,p<0.001),与Aβ状态及示踪剂种类无关。
  • 单受试者分析显示低灌注簇与低代谢拓扑分布对应良好,与潜在神经变性模式无关。
  • AD相关metaROI区分AD患者与对照:AUC氟贝他吡0.888、氟美他莫0.801,FDG-PET分别为0.915和0.832,FDG-PET略优但差异无统计学显著(所有p值高于0.05)。

核心结论

  • 参数分析显示单受试者水平灌注分布与代谢分布相当,尤其在神经变性负荷高时。
  • 作者认为早期相18F-氟贝他吡/18F-氟美他莫成像可替代18F-FDG-PET成像,因其可显示典型神经变性模式或排除神经变性存在。
  • 作者指出该发现显示淀粉样PET的成本节约能力,并支持该 modality 在临床实践中用于个体分类的常规使用。

研究设计与样本

  • 在日内瓦记忆中心评估166例受试者,涵盖认知未受损至轻度认知障碍(MCI)及痴呆。
  • 受试者接受早期相淀粉样PET(18F-氟贝他吡eFBP n=94或18F-氟美他莫eFMM n=72)及18F-FDG-PET,并评估Aβ状态。
  • 提取SUVR评估eFBP/eFMM与各自18F-FDG-PET的相关性;采用单受试者程序分析低代谢与低灌注图及Dice系数空间重叠;用ROC分析比较eFBP/eFMM与18F-FDG-PET SUVR在AD相关metaROI区分Aβ阴性健康对照与AD连续谱病例的能力。

主要发现

  • eFBP/eFMM与18F-FDG-PET SUVR呈正相关,与Aβ状态及Aβ示踪剂无关(R>0.72,p<0.001)。
  • eFBP/eFMM单受试者分析显示显著低灌注簇与低代谢拓扑对应良好,与潜在神经变性模式无关。
  • eFBP/eFMM与18F-FDG-PET SUVR在AD相关metaROI均显著区分AD患者与对照(AUCFBP=0.888;AUCFMM=0.801),18F-FDG-PET略优但差异无统计学显著(所有p值高于0.05;AUCFDG=0.915和0.832分别对应接受18F-FBP和18F-FMM评估的受试者)。

关键数值与推荐

  • eFBP/eFMM与18F-FDG-PET SUVR相关性:R>0.72,p<0.001。
  • AD相关metaROI区分AD患者与对照的AUC:eFBP 0.888、eFMM 0.801、18F-FDG-PET 0.915(对应18F-FBP评估者)和0.832(对应18F-FMM评估者),组间差异均无统计学显著(所有p值高于0.05)。

临床怎么用

  • 作者认为早期相18F-氟贝他吡/18F-氟美他莫成像可替代18F-FDG-PET成像,因其可显示典型神经变性模式或排除神经变性存在。
  • 作者指出该发现显示淀粉样PET的成本节约能力,并支持该 modality 在临床实践中用于个体分类的常规使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Alzheimer's disease (AD) neuropathologic changes are β-amyloid (Aβ) deposition, pathologic tau, and neurodegeneration. Dual-phase amyloid-PET might be able to evaluate Aβ deposition and neurodegeneration with a single tracer injection. Early-phase amyloid-PET scans provide a proxy for cerebral perfusion, which has shown good correlations with neural dysfunction measured through metabolic consumption, while the late frames depict amyloid distribution. Our study aims to assess the comparability between early-phase amyloid-PET scans and 18F-fluorodeoxyglucose (18F-FDG)-PET brain topography at the individual level, and their ability to discriminate patients. Methods: 166 subjects evaluated at the Geneva Memory Center, ranging from cognitively unimpaired to Mild Cognitive Impairment (MCI) and dementia, underwent early-phase amyloid-PET - using either 18F-florbetapir (eFBP) (n = 94) or 18F-flutemetamol (eFMM) (n = 72) - and 18F-FDG-PET. Aβ status was assessed. Standardized uptake value ratios (SUVR) were extracted to evaluate the correlation of eFBP/eFMM and their respective 18F-FDG-PET scans. The single-subject procedure was applied to investigate hypometabolism and hypoperfusion maps and their spatial overlap by Dice coefficient. Receiver operating characteristic analyses were performed to compare the discriminative power of eFBP/eFMM, and 18F-FDG-PET SUVR in AD-related metaROI between Aβ-negative healthy controls and cases in the AD continuum. Results: Positive correlations were found between eFBP/eFMM and 18F-FDG-PET SUVR independently of Aβ status and Aβ radiotracer (R>0.72, p<0.001). eFBP/eFMM single-subject analysis revealed clusters of significant hypoperfusion with good correspondence to hypometabolism topographies, independently of the underlying neurodegenerative patterns. Both eFBP/eFMM and 18F-FDG-PET SUVR significantly discriminated AD patients from controls in the AD-related metaROIs (AUCFBP = 0.888; AUCFMM=0.801), with 18F-FDG-PET performing slightly better, however not significantly (all p-value higher than 0.05), than others (AUCFDG=0.915 and 0.832 for subjects evaluated with 18F-FBP and 18F-FMM, respectively). Conclusion: The distribution of perfusion was comparable to that of metabolism at the single-subject level by parametric analysis, particularly in the presence of a high neurodegeneration burden. Our findings indicate that eFBP/eFMM imaging can replace 18F-FDG-PET imaging, as they reveal typical neurodegenerative patterns, or allow to exclude the presence of neurodegeneration. The finding shows cost-saving capacities of amyloid-PET and supports the routine use of the modality for individual classification in clinical practice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Boccalini C, Peretti DE, Ribaldi F, et al. Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2022. PMID: 35863896. doi:10.2967/jnumed.122.264256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。